ANIP vs LNTH vs RMD vs AMRX

For growth investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger pick with 43. 8% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). ResMed Inc. (RMD) offers the better valuation at 21. 8x trailing P/E (18. 8x forward), making it the more compelling value choice. Analysts rate ANI Pharmaceuticals, Inc. (ANIP) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ResMed Inc.

(RMD) is the cheapest at 21. 8x versus Amneal Pharmaceuticals, Inc. at 62. 4x. On forward P/E, ANI Pharmaceuticals, Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to +11. 0% for ResMed Inc. (RMD). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus AMRX's -54. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus Amneal Pharmaceuticals, Inc. 's 1. 17β — meaning AMRX is approximately 150% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 60% for ANI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ANI Pharmaceuticals, Inc.

(ANIP) is pulling ahead at 43. 8% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: ANI Pharmaceuticals, Inc. grew EPS 419. 2% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus 2. 4% for Amneal Pharmaceuticals, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — ANIP leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ANI Pharmaceuticals, Inc.

(ANIP) trades at 9. 2x forward P/E versus 18. 8x for ResMed Inc. — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ANIP: 47. 8% to $124. 00.

In this comparison, RMD (1.

0% yield) pays a dividend. ANIP, LNTH, AMRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +293. 8% 10Y return). Both have compounded well over 10 years (RMD: +293. 8%, AMRX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ANIP is a small-cap high-growth stock; LNTH is a small-cap quality compounder stock; RMD is a mid-cap quality compounder stock; AMRX is a small-cap quality compounder stock. RMD pays a dividend while ANIP, LNTH, AMRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.